Lalistat 1 is primarily used as a selective inhibitor of lysosomal acid lipase (LAL), an enzyme involved in lipid metabolism. It is widely applied in research settings to study the role of LAL in cellular processes, particularly in lipid storage and breakdown. By inhibiting LAL activity, Lalistat 1 helps model conditions such as Wolman disease and cholesteryl ester storage disease, which are linked to LAL deficiency. It is also used to investigate the impact of lipid accumulation on cell function, inflammation, and metabolic disorders. Due to its specificity, Lalistat 1 serves as a valuable tool in understanding the pathways involved in atherosclerosis, non-alcoholic fatty liver disease (NAFLD), and other lipid-related pathologies. Its application extends to screening potential therapeutic agents that modulate lysosomal lipid metabolism.